Vistagen Therapeutics (VTGN) Accumulated Depreciation & Amortization (2018 - 2025)
Historic Accumulated Depreciation & Amortization for Vistagen Therapeutics (VTGN) over the last 10 years, with Q1 2025 value amounting to $150000.0.
- Vistagen Therapeutics' Accumulated Depreciation & Amortization rose 1811.02% to $150000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $150000.0, marking a year-over-year increase of 1811.02%. This contributed to the annual value of $150000.0 for FY2025, which is 1811.02% up from last year.
- As of Q1 2025, Vistagen Therapeutics' Accumulated Depreciation & Amortization stood at $150000.0, which was up 1811.02% from $127000.0 recorded in Q1 2024.
- Vistagen Therapeutics' Accumulated Depreciation & Amortization's 5-year high stood at $153500.0 during Q1 2022, with a 5-year trough of $30600.0 in Q4 2022.
- Over the past 5 years, Vistagen Therapeutics' median Accumulated Depreciation & Amortization value was $40200.0 (recorded in 2021), while the average stood at $76725.0.
- Within the past 5 years, the most significant YoY rise in Vistagen Therapeutics' Accumulated Depreciation & Amortization was 6553.03% (2021), while the steepest drop was 9675.11% (2021).
- Quarter analysis of 5 years shows Vistagen Therapeutics' Accumulated Depreciation & Amortization stood at $43700.0 in 2021, then fell by 29.98% to $30600.0 in 2022, then grew by 2.94% to $31500.0 in 2023, then skyrocketed by 303.17% to $127000.0 in 2024, then increased by 18.11% to $150000.0 in 2025.
- Its Accumulated Depreciation & Amortization stands at $150000.0 for Q1 2025, versus $127000.0 for Q1 2024 and $31500.0 for Q2 2023.